Format

Send to

Choose Destination
Diabetes Obes Metab. 2018 Feb;20(2):257-269. doi: 10.1111/dom.13062. Epub 2017 Aug 22.

Therapeutic application of GPR119 ligands in metabolic disorders.

Author information

1
Department of Pharmacy, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
2
Department of Pharmacy, College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea.

Abstract

GPR119 belongs to the G protein-coupled receptor family and exhibits dual modes of action upon ligand-dependent activation: pancreatic secretion of insulin in a glucose-dependent manner and intestinal secretion of incretins. Hence, GPR119 has emerged as a promising target for treating type 2 diabetes mellitus without causing hypoglycaemia. However, despite continuous efforts by many major pharmaceutical companies, no synthetic GPR119 ligand has been approved as a new class of anti-diabetic agents thus far, nor has any passed beyond phase II clinical studies. Herein, we summarize recent advances in research concerning the physiological/pharmacological effects of GPR119 and its synthetic ligands on the regulation of energy metabolism, and we speculate on future applications of GPR119 ligands for the treatment of metabolic diseases, focusing on non-alcoholic fatty liver disease.

KEYWORDS:

GPR119; metabolic diseases; non-alcoholic fatty liver disease; physiological/pharmacological effects; synthetic ligands; type 2 diabetes mellitus

PMID:
28722242
DOI:
10.1111/dom.13062
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center